Safety and efficacy of multi-kinase inhibitor plus endostar treatment in patients with metastatic renal cell carcinoma and pleural effusion  

作　　者：Wei Luan Wenxin Li 

机构地区：[1]Departments of Oncology, Inner Mongolia People's Hospital

出　　处：《Oncology and Translational Medicine》2018年第1期10-12,共3页肿瘤学与转化医学（英文版）

摘　　要：Objective The aim of this study was to evaluate the safety and efficacy of multi-kinase inhibitor plus endostar treatment in patients with metastatic renal cell carcinoma(m RCC) and pleural effusion. Methods A total of 10 patients with m RCC(8 clear-cell RCCs, 1 papillary RCC, 1 chromophobe RCC) with pleural effusion from January 2014 to October 2015 were recruited. Four patients received sorafenib(400 mg, twice daily), while six received sunitinib(50 mg, once daily; 2 weeks on and 1 week off). All patients received multi-kinase inhibitor plus pleural cavity perfusion of endostar(15 mg on days 1–4 for 1 or 2 weeks). Results The response rate of pleural effusion was 70%. Adverse reactions were limited and mild.Conclusion The regimen of multi-kinase inhibitor plus pleural cavity perfusion of endostar was both effective and safe for the treatment of patients with m RCC with pleural effusion, and may control local symptoms.Objective The aim of this study was to evaluate the safety and efficacy of multi-kinase inhibitor plus endostar treatment in patients with metastatic renal cell carcinoma(m RCC) and pleural effusion. Methods A total of 10 patients with m RCC(8 clear-cell RCCs, 1 papillary RCC, 1 chromophobe RCC) with pleural effusion from January 2014 to October 2015 were recruited. Four patients received sorafenib(400 mg, twice daily), while six received sunitinib(50 mg, once daily; 2 weeks on and 1 week off). All patients received multi-kinase inhibitor plus pleural cavity perfusion of endostar(15 mg on days 1–4 for 1 or 2 weeks). Results The response rate of pleural effusion was 70%. Adverse reactions were limited and mild.Conclusion The regimen of multi-kinase inhibitor plus pleural cavity perfusion of endostar was both effective and safe for the treatment of patients with m RCC with pleural effusion, and may control local symptoms.

关 键 词：RENAL cell carcinoma PLEURAL EFFUSION multi-kinase INHIBITOR ENDOSTAR 

分 类 号：R73[医药卫生—肿瘤]